Grant: Discovery Grants Program - Individual
Dalhousie University
$34,000.00
Development of Quantitative Multi-Contrast Molecular Imaging
FY 2024-25
Summary
The Problem
There are a number of important yet unanswered biological questions about how cells and molecules behave in the body (in vivo). Although researchers have discovered a large amount of information by using cutting edge tools to map individual cells down to the genome, in many cases we still don't understand how populations of cells actually interact and behave in the body. Several imaging techniques have been developed that allow monitoring of cells over time in vivo, but the techniques that offer the best quality images do not provide quantitative information, limiting our observations. Additionally, although we have developed technologies to image various different types of contrast agents like gadolinium (Gd) or iron oxide, almost all studies only use one agent at a time.
The Solution
Magnetic resonance imaging (MRI) is well known for its ability to image a large variety of materials, from human tissue to concrete. It can also be used to track individual cells and molecules that have been labeled with a contrast agent. This program will develop and evaluate MRI-based quantitative measurements of biological agents tagged with superparamagnetic iron oxide (SPIO) in combination with a special Gd agent that can indicate when cells are dying, also known as apoptosis.
My project will have three distinct steps in it. In the first step, we will optimize a special type of MRI pulse sequence called magnetic resonance fingerprinting (MRF). Our lab has implemented this technique for imaging both SPIO and Gd, but right now it is not fast enough to use in vivo preclinically. We will therefore work to make this technique faster and even more accurate.
The second step of the program will use MRF to look at SPIO-labeled cells and the Gd contrast agent that measures apoptosis. Because this agent is modified in cells that are dying, it has two unique forms - a) the version that gets trapped only in dying cells, and b) the precursor form of the probe that can get into any cells but will eventually be cleared. We will use MRF to distinguish between the different versions of the probe and still measure the labeled cells to see if there is a response to e.g. cancer therapy.
The last part of the program will be to optimize the specialized data analysis for this project. We will look at an emerging type of automated analysis called radiomics, which can be used to automatically pick out important features in large amounts of imaging data that are not obvious to the human eye.
The Impact
This program of research describes a coherent sequence of projects that will develop and validate novel tools for simultaneous MRI-based quantification of two types of cells and molecules labeled with SPIO or Gd. This work will result in advanced imaging technologies that have broad applicability in a number of biological fields and can improve understanding of basic immunological behavior, particularly with respect to cancer therapies.
Program
Discovery Grants Program - Individual
Recipient
Location
Nova Scotia, Canada
Recipient Type
Academia
Type
Grant
Source
NSERC's Awards Data
As published
Application id
RGPIN-2021-02990
Name nom
Brewer, Kimberly
Department département
Radiology
Organization id
79
Institution établissement
Dalhousie University
Province en
Nova Scotia
Province fr
Nouvelle-Écosse
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2024
Competition year année de concours
2021
Award amount
34000
Program id
RGPIN
Program name en
Discovery Grants Program - Individual
Program name fr
Programme de subventions à la découverte - individuelles
Group en
DISCOVERY RESEARCH
Group fr
RECHERCHE AXÉE SUR LA DÉCOUVERTE
Committee code
1505
Committee name en
Physics
Committee name fr
Physique
Area of application code
518
Area of application group en
Manufacturing processes and products
Area of application group fr
Procédés et produits industriels
Area of application en
Medical equipment and apparatus
Area of application fr
Appareils et instruments médicaux
Research subject code
3114
Research subject group en
Physics
Research subject group fr
Physique
Research subject en
Biological and Medical Physics
Research subject fr
Physique biologique et médicale
Field of research list names en
Not available
Field of research list names fr
Non disponible
Socioeconomic objective list names en
Not available
Socioeconomic objective list names fr
Non disponible
Application title
Development of Quantitative Multi-Contrast Molecular Imaging
Keywords
molecular imaging; magnetic resonance imaging (mri); magnetic resonance fingerprinting (mrf); radiomics; quantitative imaging; r2* mapping; immune cell tracking
Application summary
The Problem
There are a number of important yet unanswered biological questions about how cells and molecules behave in the body (in vivo). Although researchers have discovered a large amount of information by using cutting edge tools to map individual cells down to the genome, in many cases we still don't understand how populations of cells actually interact and behave in the body. Several imaging techniques have been developed that allow monitoring of cells over time in vivo, but the techniques that offer the best quality images do not provide quantitative information, limiting our observations. Additionally, although we have developed technologies to image various different types of contrast agents like gadolinium (Gd) or iron oxide, almost all studies only use one agent at a time.
The Solution
Magnetic resonance imaging (MRI) is well known for its ability to image a large variety of materials, from human tissue to concrete. It can also be used to track individual cells and molecules that have been labeled with a contrast agent. This program will develop and evaluate MRI-based quantitative measurements of biological agents tagged with superparamagnetic iron oxide (SPIO) in combination with a special Gd agent that can indicate when cells are dying, also known as apoptosis.
My project will have three distinct steps in it. In the first step, we will optimize a special type of MRI pulse sequence called magnetic resonance fingerprinting (MRF). Our lab has implemented this technique for imaging both SPIO and Gd, but right now it is not fast enough to use in vivo preclinically. We will therefore work to make this technique faster and even more accurate.
The second step of the program will use MRF to look at SPIO-labeled cells and the Gd contrast agent that measures apoptosis. Because this agent is modified in cells that are dying, it has two unique forms - a) the version that gets trapped only in dying cells, and b) the precursor form of the probe that can get into any cells but will eventually be cleared. We will use MRF to distinguish between the different versions of the probe and still measure the labeled cells to see if there is a response to e.g. cancer therapy.
The last part of the program will be to optimize the specialized data analysis for this project. We will look at an emerging type of automated analysis called radiomics, which can be used to automatically pick out important features in large amounts of imaging data that are not obvious to the human eye.
The Impact
This program of research describes a coherent sequence of projects that will develop and validate novel tools for simultaneous MRI-based quantification of two types of cells and molecules labeled with SPIO or Gd. This work will result in advanced imaging technologies that have broad applicability in a number of biological fields and can improve understanding of basic immunological behavior, particularly with respect to cancer therapies.